| [1] |
SUN Caihong, HU Taotao, XIAO Xingxing, YUAN Mengnan, JIANG Simin, CHEN Yinqi, RUAN Guodong.
The world's first PD-1/VEGF bispecific antibody:ivonescimab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1290-1296.
|
| [2] |
GENG Biao, SUN Zhengui, ZHAO Chunyang, CHEN Xingwu.
Myeloid-derived suppressor cells in predicting the efficacy and prognosis of PD-1 inhibitor combined with chemotherapy in non-small cell lung cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1076-1083.
|
| [3] |
LIU Dewei, WU Dong, HUANG Dan, ZHAO Xuanna, WU Bin.
Research progress on non-coding RNA mediated apoptosis in lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 968-976.
|
| [4] |
CUI Hanyu, HU Changping.
Research progress on the role of macrophage polarization in cardiovascular diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 548-555.
|
| [5] |
DENG Yanru, CAO Gexi, LI Ying, LI Yajing, DONG Zhanjun.
Research progress on pharmacokinetic interactions of sodium-glucose co-transporter 2 inhibitors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 570-576.
|
| [6] |
WANG Long, WANG Yuchen, GUO Yilin, WU Jinhui.
Engineered bacteria modulate tumor-associated macrophages to enhance immunotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 297-312.
|
| [7] |
GAO Wanli, ZHOU Qichun, WANG Sumei.
Fructus Akebiae induces apoptosis via regulating ROS-mediated PI3K-Akt signaling pathway in non-small cell lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 339-346.
|
| [8] |
DUAN Yuxin, ZHANG Yanni, BAI Yi, YU Jinyao, SUN Jiayi, WANG Zejie, LI Ling, YE Qifa.
Progress of macrophage regulation mechanism in acute renal injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(1): 110-117.
|
| [9] |
CUI Yanjun, MA Tian, LIU Yi, JIAO Ling, CHAI Aijun, FAN Rongrong, LIU Yanguo, LUO Xing-xian, HUANG Lin, ZHANG Xiaohong.
A rapid health technology assessment of camrelizumab in combination with chemotherapy for the first-line treatment of locally advanced/metastatic non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(7): 775-784.
|
| [10] |
HE Ye, WANG Yinhua, GENG Biao, BAO Xing.
The relationship between the ratio and dynamic changes of lymphocytes/monocytes and the efficacy of PD-1 inhibitors in the treatment of advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(5): 569-575.
|
| [11] |
CAO Zhiwen, YAN Guijun.
Research progress of uterine endometrial epithelial cell organoids in the field of reproduction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(5): 576-582.
|
| [12] |
LI Zhanbo, DU Kaifeng, JIANG Zhilong, GAO Jiameng, CHEN Mengjie, MA Yuan, CHEN Zhihong.
Analysis of the effect of fudosteine on induced sputum components in patients with stable neutrophil-dominated COPD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 362-369.
|
| [13] |
BAI Haodong, SHA Bingxian, Ambedkar Kumar Yadav, XU Xianghuai, YU Li .
Targeted biotherapy for chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 377-382.
|
| [14] |
ZHANG Ting, SUN Rong, YANG Yong, LIU Weichun, YUAN Yuping, JU Xu, WANG Qian.
Mechanism and treatment of mucous hypersecretion in chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 383-391.
|
| [15] |
WANG Xiaochuan, WANG Hanchao, YAO Yu, LI Li, HE Gaoyan, LI Bo, ZHU Tao.
Clinical features, risk factors and treatment of type 2 diabetes mellitus in patients with acute exacerbation of chronic obstructive pulmonary disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 392-400.
|